Ultragenyx: Two Gene Therapy Catalysts and a Novel Endpoint Set the Stage for a Historic Second Half

Record Revenue, Bigger Ambitions

Ultragenyx entered the second half of 2026 on a commercial high. The company delivered $214 million in total revenue for Q2, the highest quarterly figure in its history, underpinning management's reaffirmed full-year guidance. Sanfilippo syndrome is one of two rare diseases for which the company has a gene therapy under FDA review, and the commercial engine is clearly moving beyond its legacy products. “The commercial team delivered the highest quarterly revenue in the history of the company, which supports our reaffirmed full-year revenue guidance.” — Emil Kakkis, Chief Executive Officer and President · 2026-08-04 Crysvita grew on patient additions in Latin America and Turkey, while Evkeeza delivered 50% year-over-year growth in the quarter.

The company's fundamentals reflect the investment phase: Total revenue reached $136 million in Q1 2026 per the most recent filing, with the Q2 call reporting $214 million—a sharp acceleration as the commercial organization scales. Net cash used in operations fell to $97 million for Q2, down from the first quarter, as the company manages its burn while making pre-launch investments.

Two Gene Therapies, One Deadline Double

The two PDUFA dates—DTX-401 for GSD1a on August 23 and UX-111 for Sanfilippo syndrome on September 19—are just weeks apart. Management described parallel gene therapy BLA processes, including manufacturing inspections and information requests. “We remain confident in the work our team is doing to support these applications.” — Emil Kakkis, Chief Executive Officer and President · 2026-08-04 The company already has a field force experienced in rare disease launches, and its claim of "first-ever treatments for diseases with significant unmet needs" underscores the urgency.

That urgency is also a commercial advantage. With more than 200 payer engagements done, and a network of Qualified Treatment Centers under contract, the company says it is ready for day-one access. The revenue potential is significant—adding these two products could help bridge the gap to profitability.

Angelman: A More Powerful, But Unconventional, Bet

The third catalyst is the ASPIRE study in Angelman syndrome, whose top-line data is expected in September or October. The design splits statistical alpha between the Bayley-4 cognitive raw score (80%) and the Multi-Domain Responder Index (MDRI, 20%). Management argues the MDRI is more sensitive because it captures clinically meaningful changes across multiple domains—cognition, communication, sleep, behavior, and motor—rather than relying on a single measure. “We think a five or six-point change, for example, in the Bayley should be sufficient to achieve significance, and that would be the six-point level is considered clinically meaningful.” — Emil Kakkis, Chief Executive Officer and President · 2026-08-04 The MDRI was already used successfully in the MEPSEVII program, and its design may help filter out placebo noise.

This marks a significant departure from the standard single-endpoint approach, and it's not without risk. The FDA has not previously approved a drug based on MDRI as a primary co-endpoint. But the company's phase I/II data show long-lasting gains—patients have now been on therapy for an average of three years, with some approaching five—which bolsters confidence.

With a disease like Sanfilippo syndrome, there's no greater urgency to treat.

Prior calls have already flagged the statistical design as a key differentiator. “The MDRI has been a very robust and consistent measure just in its nature because it's multiple domains that we've seen strong results.” — Emil Kakkis, Chief Executive Officer and President · 2026-05-06 But the company also acknowledged the risk of variability in the sham-controlled trial, a theme that recurred in Q&A. “We've said the second half, but you can tell by when last patient in was roughly when the trial should have the last patient out.” — Emil Kakkis, Chief Executive Officer and President · 2026-05-06 The timing and the design remain the two biggest swing factors for the stock.

The 2027 Profit Equation

Management's path to profitability in 2027 rests on three levers: continued double-digit revenue growth, disciplined expense management (combined R&D and SG&A expected down at least 15% next year), and monetization of two priority review vouchers (PRVs) that would accompany approvals. Howard Horn noted that the company plans to sell both PRVs, with proceeds bolstering the balance sheet. “Net cash used in operations for the quarter was $97 million, a significant decrease from the first quarter and consistent with the expectations we discussed on our last call.” — Howard Horn, Chief Financial Officer · 2026-08-04 The company ended Q2 with $436 million in cash and marketable securities, plus opportunities to monetize more PRVs down the road.

However, the balance sheet remains stretched. Liabilities to assets have climbed to 117.7% as of Q1 2026, reflecting the company's heavy investment phase. Liabilities-to-assets ratio rose from 88% a year ago, showing how much the company has leaned on debt and deferred revenues to fund its pipeline. The two gene therapy launches are essential to reversing that trajectory.